Drugs / Lepetegravir
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05585307 | Oct 2022 → Feb 2024 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06613685 | Oct 2024 → Mar 2026 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT06544733 | Aug 2024 → Jan 2028 expected | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lepetegravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544733 ↗ |
| Known as | GS-1720 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585307 ↗ |
| Action | Inhibit | “an oral, long-acting integrase strand transfer inhibitor (INSTI)” NCT06613685 ↗ |
| Route | Oral | “Administered orally” NCT05585307 ↗ |